Talk:Deferiprone

This is the talk page for discussing improvements to the Deferiprone article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Deferiprone.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

cormedix

just a note - today I removed the following: "Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.(ref)http://www.cormedix.com/pipeline_CRMD001.php(/ref)." This is no longer true - see here http://www.dailyfinance.com/2013/03/27/cormedix-reports-year-end-2012-financial-results/ and here http://philadelphia.citybizlist.com/article/sec-filing-cormedix-terminates-agreement-shiva-biomedical. We should have had some MEDRS compliant source on this and we never did... Jytdog (talk) 10:42, 1 October 2013 (UTC)[reply]

Inhibition of HIV-1 gene expression

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A

Mainul Hoque, Hartmut M Hanauske-Abel, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi Gandolfi, Myung Hee Park, Tsafi Pe'eryEmail author and Michael B Mathews author

Retrovirology 20096:90

DOI: 10.1186/1742-4690-6-90

https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-6-90

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infect ... http://dx.doi.org/10.1371/journal.pone.0154842

The finding that the medicinal chelator deferiprone removes, without eliciting viral resistance noticeable in our system, the HIV-1 genome by apoptotic fragmentation preferentially of the infected cells’ DNA, defines a unique antiretroviral profile. However, HIV-1 infection usually is not associated with iron overload, and therefore any as-is repurposing of orally administered deferiprone for its antiretroviral side-activity must not be expected to be benign: We have not shown oral deferiprone to be safe or effective for anti(retro)viral indications.

It remains to be established whether any of the currently available oral preparations of deferiprone, or the anticipated chemical optimization of this pioneer drug into non-chelating inhibitors of DOHH, will translate into real benefits for persons living with HIV-AIDS. Based on the preclinical and clinical results presented here and earlier [28,43,45,46], a follow-up clinical trial evaluating the safety, efficacy, and pharmacokinetics of deferiprone in HIV-positive subjects has been conducted and is registered at ClinicalTrial.gov (NCT02456558).

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154842 — Preceding unsigned comment added by 95.33.229.87 (talk) 19:31, 24 August 2016 (UTC)[reply]

That is really exciting but it is a primary source and per WP:MEDRS we use literature reviews to source content in WP. Are you aware of any that discuss the work published in PLoS? Jytdog (talk) 05:00, 25 August 2016 (UTC)[reply]